What are the side effects of Tikosyn (dofetilide)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Tikosyn (Dofetilide)

Tikosyn (dofetilide) can cause serious side effects, most notably a potentially fatal type of abnormal heartbeat called Torsade de Pointes, which requires mandatory hospitalization for the first 3 days of treatment to establish the appropriate dose and monitor for complications.

Major Side Effects

Cardiac Side Effects

  • Torsade de Pointes: The most serious side effect, occurring in 0.8-1.5% of patients taking oral dofetilide and 3-4% with intravenous administration 1
  • QT interval prolongation: Dose-dependent effect that can lead to Torsade de Pointes 2, 3
  • Bradycardia: Abnormally slow heart rate 4
  • Hypotension: Low blood pressure 4

Common Non-Cardiac Side Effects

  • Headache: One of the most frequently reported side effects 2
  • Chest pain: Common complaint among users 2
  • Dizziness: May affect balance and daily activities 2

Risk Factors for Serious Side Effects

Patients at higher risk for developing Torsade de Pointes include:

  • Female gender
  • Advanced age
  • Hypokalemia (low potassium)
  • Hypomagnesemia (low magnesium)
  • Bradycardia
  • Congestive heart failure
  • Renal dysfunction
  • Baseline QT prolongation
  • Concomitant use of other QT-prolonging medications 5

Drug Interactions

Contraindicated Medications

Dofetilide should NOT be taken with:

  • Verapamil
  • Cimetidine
  • Ketoconazole
  • Trimethoprim alone or with sulfamethoxazole
  • Prochlorperazine
  • Megestrol
  • Dolutegravir
  • Hydrochlorothiazide (alone or in combination) 2, 5

These medications can increase the risk of QT prolongation and Torsade de Pointes when combined with dofetilide.

Monitoring Requirements

Due to the risk of serious arrhythmias:

  • Treatment must be initiated in a hospital setting
  • Continuous cardiac monitoring for at least 3 days
  • ECG monitoring before and after dosing
  • Regular assessment of kidney function
  • Monitoring of electrolytes, particularly potassium and magnesium 2
  • Discontinuation if QT interval exceeds 500 ms or increases by >60 ms from baseline 5

Dosing Considerations

  • Dosing must be individualized based on QTc interval and renal function
  • Dose adjustment is required for patients with renal impairment
  • Dofetilide is contraindicated in patients with creatinine clearance <20 mL/min 4

Signs of Electrolyte Imbalance

Patients should be alert for signs of electrolyte imbalance, which can increase the risk of arrhythmias:

  • Severe diarrhea
  • Unusual sweating
  • Vomiting
  • Loss of appetite
  • Increased thirst 2

When to Seek Immediate Medical Attention

Patients should call their doctor and go to the hospital immediately if they:

  • Feel faint
  • Become dizzy
  • Experience a fast heartbeat 2

These symptoms could indicate the development of a serious arrhythmia requiring immediate medical intervention.

Special Populations

Dofetilide should be used with caution in:

  • Elderly patients
  • Patients with heart failure
  • Patients with structural heart disease
  • Patients with renal impairment (requires dose adjustment) 4, 5

Understanding these side effects and following proper monitoring protocols is essential for the safe use of Tikosyn (dofetilide) in managing atrial fibrillation and atrial flutter.

References

Research

Dofetilide: a new class III antiarrhythmic agent.

The Canadian journal of cardiology, 2001

Research

Dofetilide-induced long QT and torsades de pointes.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2007

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Safe Use of Antibiotics with Dofetilide

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.